Rigel Pharmaceuticals
RIGL
120 hedge funds and large institutions have $187M invested in Rigel Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 43 increasing their positions, 36 reducing their positions, and 11 closing their positions.
117% more call options, than puts
Call options by funds: $524K | Put options by funds: $242K
19% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 36
11% more capital invested
Capital invested by funds: $168M → $187M (+$18.6M)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
0% more funds holding
Funds holding: 120 → 120 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$3.95M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$1.99M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$1.74M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.08M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$784K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$1.76M |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.57M |
| 3 |
SCM
Sio Capital Management
New York
|
-$704K |
| 4 |
SIM
Spark Investment Management
New York
|
-$604K |
| 5 |
SAM
Senzar Asset Management
New York
|
-$431K |
RIGL Hedge Fund Activity: Q2 2016 in Review
120 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q2 2016, worth a combined $187M — up 11% from $168M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new RIGL positions and 11 closed out — a net gain of 1 holder — while 43 added to existing stakes and 36 trimmed.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $3.95M. The largest seller was Marshall Wace, exiting entirely with an estimated $1.76M sold.
- 120 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $187M of Rigel Pharmaceuticals stock for Q2 2016, up 11% quarter-over-quarter.
- 12 funds opened new Rigel Pharmaceuticals positions in Q2 2016 and 11 closed out, a net change of +1 holder.
- The largest Rigel Pharmaceuticals buyer in Q2 2016 was JP Morgan Chase, an estimated $3.95M added.
- The largest Rigel Pharmaceuticals seller in Q2 2016 was Marshall Wace, an estimated $1.76M sold.
Based on aggregated 13F filings for Q2 2016.